Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Media, Education & Engagement
Media & CommunicationAcademic & Trade Publications
Media, Education & Engagement

Fierce Biotech

Data updated

United States

Biotechnology industry publication with recurring coverage of psychedelic drug-development programs and deal activity.

Media & Communication Snapshot

Academic & Trade Publications

Cadence

Daily

Access

Registration

Psychedelic Focus

Psychedelic-Adjacent Focus

Verification

Verified

Audience

Industry ProfessionalsInvestorsResearchers

Coverage Focus

Business & IndustryResearch & SciencePolicy & Legal

Media Notes

Fierce Biotech is a long-running biotech industry news outlet publishing daily on R&D, financing, clinical trials and regulatory developments. It covers psychedelics regularly as part of its neuroscience and dealmaking beat, with articles on the AbbVie-Gilgamesh deals, Lykos's MDMA filing and investor interest in the sector. Content is free to read with registration and newsletter sign-up encouraged.

Verification

Verified

Last Verified

Jul 11, 2026

Primary Media Link

Source Evidence

Fierce Biotech

https://www.fiercebiotech.com/

FDA advisers to weigh first psychedelic therapy

https://www.fiercebiotech.com/biotech/fda-advisers-weigh-first-psychedelic-therapy-early-june

Quick Facts

Type
Other
HQ
United States
Website
Visit